Trial · NCT00504894
Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes
NCT00504894, Phase 4, Terminated, Weill Medical College of Cornell University; results first posted 2017-05-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes. Trials, record NCT00504894. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00504894
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes
- NCT number
- NCT00504894
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 60 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Healthy
- Interventions
- Placebo, Propofol, Thiopental
- First posted
- 2007-07-20
- Last updated
- 2021-07-15
- Results first posted
- 2017-05-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood-oxygen-level-dependent Significant Activation Cluster | for 90 minutes after the drug/placebo was commenced | Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was \< 0.001, and then the P value was \< 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was \< 0.001, and then the P value was \< 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported. |
| Secondary | Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory | for 90 minutes after the drug/placebo was commenced | Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was \< 0.001, and then the P value was \< 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was \< 0.001, and then the P value was \< 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Blood-oxygen-level-dependent Significant Activation Cluster | for 90 minutes after the drug/placebo was commenced | Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.~Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.~Of the 19 thiopental subjects recruited, no subjects' data was excluded. | BOLD significantly activated clusters | NUMBER |
| SECONDARY | Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory | for 90 minutes after the drug/placebo was commenced | Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.~Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.~Of the 19 thiopental subjects recruited, no subjects' data was excluded. | BOLD significantly activated clusters | NUMBER |
Source ClinicalTrials.gov
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Blood-oxygen-level-dependent Significant Activation Cluster | Placebo | Right Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Propofol | Right Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Thiopental | Right Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Placebo | Left Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Propofol | Left Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Thiopental | Left Amygdala | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Placebo | Right Hippocampus | 1 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Propofol | Right Hippocampus | 0 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Thiopental | Right Hippocampus | 0 | BOLD significantly activated clusters | |
| Blood-oxygen-level-dependent Significant Activation Cluster | Placebo | Left Hippocampus | 1 | BOLD significantly activated clusters |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 20 | |
| Overall Study | STARTED | Propofol | 21 | |
| Overall Study | STARTED | Thiopental | 19 | |
| Overall Study | COMPLETED | Placebo | 17 | |
| Overall Study | COMPLETED | Propofol | 18 | |
| Overall Study | COMPLETED | Thiopental | 19 | |
| Overall Study | NOT COMPLETED | Placebo | 3 | |
| Overall Study | NOT COMPLETED | Propofol | 3 | |
| Overall Study | NOT COMPLETED | Thiopental | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 20 |
| Total, all-cause mortality | Propofol | 0 | 21 |
| Total, all-cause mortality | Thiopental | 0 | 19 |
| Total, other adverse events | Placebo | 0 | 20 |
| Total, other adverse events | Propofol | 0 | 21 |
| Total, other adverse events | Thiopental | 0 | 19 |
| Total, serious adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Propofol | 0 | 21 |
| Total, serious adverse events | Thiopental | 0 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26174294 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K08GM083213 | The Effect of Intravenous Anesthetics on Fear Learning & Memory Systems in Humans | PRYOR, KANE | WEILL MEDICAL COLL OF CORNELL UNIV | NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES | 2008 to 2011 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00504894
GET https://conductscience.org/api/trials/v1/NCT00504894/results?page=2